Press releases
- Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference
- Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- Insmed to Host Commercial Webinar on June 4, 2024
- Insmed Announces Pricing of $650 Million Public Offering of Common Stock
- Insmed Announces Proposed $500 Million Public Offering of Common Stock
- Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis
- Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis
- Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Conference Plenary Session
More ▼
Key statistics
As of last trade Insmed Inc (0JAV:LSE) traded at 64.31, -8.85% below its 52-week high of 70.55, set on Jun 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 64.31 |
Average volume | 2.23k |
---|---|
Shares outstanding | 163.08m |
Free float | 161.43m |
P/E (TTM) | -- |
Market cap | 10.52bn USD |
EPS (TTM) | -5.23 USD |
Data delayed at least 20 minutes, as of Jul 02 2024 18:42 BST.
More ▼